A gene sets approach for identifying prognostic gene signatures for outcome prediction

Seon-Young Kim; Yong Sung Kim
January 2008
BMC Genomics;2008, Vol. 9, Special section p1
Academic Journal
Background: Gene expression profiling is a promising approach to better estimate patient prognosis; however, there are still unresolved problems, including little overlap among similarly developed gene sets and poor performance of a developed gene set in other datasets. Results: We applied a gene sets approach to develop a prognostic gene set from multiple gene expression datasets. By analyzing 12 independent breast cancer gene expression datasets comprising 1,756 tissues with 2,411 pre-defined gene sets including gene ontology categories and pathways, we found many gene sets that were prognostic in most of the analyzed datasets. Those prognostic gene sets were related to biological processes such as cell cycle and proliferation and had additional prognostic values over conventional clinical parameters such as tumor grade, lymph node status, estrogen receptor (ER) status, and tumor size. We then estimated the prediction accuracy of each gene set by performing external validation using six large datasets and identified a gene set with an average prediction accuracy of 67.55%. Conclusion: A gene sets approach is an effective method to develop prognostic gene sets to predict patient outcome and to understand the underlying biology of the developed gene set. Using the gene sets approach we identified many prognostic gene sets in breast cancer.


Related Articles

  • Analysis of BRCA1 and BRCA2 Mutations in Southern Iranian Breast Cancer Patients. Fattahi, M. J.; Mojtahedi, Z.; Karimaghaee, N.; Talei, A. R.; Banani, S. J.; Ghaderi, A. // Archives of Iranian Medicine (AIM);Nov2009, Vol. 12 Issue 6, p584 

    The germline mutations of breast cancer susceptibility genes 1 (BRCA1) and breast cancer susceptibility genes 1 (BRCA2) have been associated with a significant increase in breast cancer risk and certain other cancers. Among the most known mutations in these tumor suppressor genes are 5382insC...

  • Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines. Li, Lijin; Goedegebuure, Peter; Mardis, Elaine R.; Ellis, Matthew J. C.; Xiuli Zhang; Herndon, John M.; Fleming, Timothy P.; Carreno, Beatriz M.; Hansen, Ted H.; Gillanders, William E. // Cancers;2011, Vol. 3 Issue 4, p4191 

    New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time...

  • Common germline polymorphisms associated with breast cancer-specific survival. Pirie, Ailith; Qi Guo; Kraft, Peter; Canisius, Sander; Eccles, Diana M.; Rahman, Nazneen; Nevanlinna, Heli; Chen, Constance; Khan, Sofia; Tyrer, Jonathan; Bolla, Manjeet K.; Qin Wang; Dennis, Joe; Michailidou, Kyriaki; Lush, Michael; Dunning, Alison M.; Shah, Mitul; Czene, Kamila; Darabi, Hatef; Eriksson, Mikael // Breast Cancer Research;2015, Vol. 17 Issue 1, p1 

    Introduction: Previous studies have identified common germline variants nominally associated with breast cancer survival. These associations have not been widely replicated in further studies. The purpose of this study was to evaluate the association of previously reported SNPs with breast...

  • The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients. Elshimali, Yahya I.; Khaddour, Husseina; Sarkissyan, Marianna; Wu, Yanyuan; Vadgama, Jaydutt V. // International Journal of Molecular Sciences;Sep2013, Vol. 14 Issue 9, p18925 

    Qualitative and quantitative testing of circulating cell free DNA (CCFDNA) can be applied for the management of malignant and benign neoplasms. Detecting circulating DNA in cancer patients may help develop a DNA profile for early stage diagnosis in malignancies. The technical issues of...

  • Ariad patent decision points to description dilemma. Perks, Bea // Nature Medicine;May2010, Vol. 16 Issue 5, p500 

    The article focuses on the decision of a U.S. federal judge to overturn the patent of Myriad Genetics on breast cancer genes BRCA1 and BRCA2.

  • RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. Rae, James M.; Leyland-Jones, Brian; Regan, Meredith; Thompson, Alastair M. // JNCI: Journal of the National Cancer Institute;5/13/2015, Vol. 107 Issue 5, p1 

    A letter to the editor is presented in response to the article "Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies" by M. P. Goetz and colleagues in the 2015.

  • CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Lan Jiang; Jieqiong Deng; Xun Zhu; Jian Zheng; Yonghe You; Na Li; Hongchun Wu; Jiachun Lu; Yifeng Zhou // Breast Cancer Research;2012, Vol. 14 Issue 4, p1 

    Introduction: It has been demonstrated that the interplay of adhesion molecule CD44 and its ligands can regulate cancer cell proliferation, migration and invasion, as well as tumor-associated angiogenesis and is related to breast cancer patient survival. In this two-stage, case control study, we...

  • Predictors of Response to Therapy.  // Hem/Onc Today;4/25/2008 Breast Cancer Supplement, Vol. 9, p3 

    The article focuses on the advances in predicting the response of patients to cancer treatment. Gene expression profiling has been proven efficient in classifying breast cancer and predicting prognosis and therapy sensitivity. The article explains the innovative approaches related to genomic...

  • Looking to the Future.  // Hem/Onc Today;4/25/2008 Breast Cancer Supplement, Vol. 9, p25 

    The article presents an outlook for breast cancer treatment. It mentions the advent of genomic technologies and molecular predictors for breast cancer classification and treatment. It argues that the development of genomic predictors such as MammaPrint and Oncotype DX, are small but relevant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics